BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Biotech Bay

  ITUS Corporation Terminates at-the-Market Offering

  The Company had not sold any shares, and will no longer offer any shares, under this program.

  December 12, 2017

   · 

  2 min read
• Policy

  Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot

  Indivior today announces that the FDA has accepted the NDA for RBP-7000, an investigational, once-monthly injectable risperidone in the ATRIGEL delivery system for the treatment of schizophrenia.

  December 12, 2017

   · 

  6 min read
• Pharm Country

  Only Generic for Kenalog-40 Injection Just Approved: Available Through Amneal Biosciences

  Poised to launch, the product will be sold in 1 mL single-dose vials as well as in 5 mL and 10 mL multiple dose vials.

  December 12, 2017

   · 

  2 min read
• Drug Development

  Realm Therapeutics Announces First Patient Dosed in Phase II Study of PR013 for the Treatment of Allergic Conjunctivitis

  The study is being conducted in the United States and top line data is expected in Q2 2018.

  December 12, 2017

   · 

  4 min read
• Business

  Cyclenium Pharma Announces Drug Discovery Collaboration Agreement with Ono Pharmaceutical

  Cyclenium will receive an upfront payment and research funding from Ono, as well as development milestones and royalties on marketed products.

  December 12, 2017

   · 

  3 min read
• Business

  Neon Therapeutics Expands Board of Directors With Leading Experts in Cancer Drug Discovery and Corporate Finance

  Neon Therapeutics announced the expansion of the company’s Board of Directors with the addition of leading experts in translational cancer drug discovery and corporate finance.

  December 12, 2017

   · 

  3 min read
• Business

  Palleon Pharmaceuticals Signs Exclusive License Agreement with King’s College London for Intellectual Property Related to Glycoimmune Checkpoints to Treat Cancer

  This agreement gives Palleon the exclusive rights to a patent portfolio that will facilitate the development of drugs that target Glycoimmune Checkpoints, a novel approach to overcoming resistance to first-generation immuno-oncology drugs.

  December 12, 2017

   · 

  3 min read
• Policy

  Alnylam Completes Submission of New Drug Application to the FDA for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

  The rolling submission began on November 15, 2017 with the nonclinical and chemistry, manufacturing and controls components submitted, and now submission of the clinical data completes the filing.

  December 12, 2017

   · 

  10 min read
• Drug Development

  GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase I/II Trial for GMI-1271

  This translational research provides important evidence that elucidates how treatment with GMI-1271 appears to be improving sensitivity to chemotherapy.

  December 12, 2017

   · 

  7 min read
• FDA

  Omeros Corporation Announces FDA Approval of OMIDRIA for Use in Pediatric Patients

  FDA also granted OMIDRIA an additional six months of U.S. market exclusivity.

  December 12, 2017

   · 

  5 min read